<PAGE>
<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
THE COOPER COMPANIES, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.10 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities
216648402
----------------------
(CUSIP Number)
Harold L. Schneider, Esq.
Tenzer Greenblatt LLP
405 Lexington Avenue, New York, New York 10174 (212) 573-4348
--------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notice and
Communications)
August 27, 1996
------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with the statement [ ]. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be 'filed' for the purpose of Section 18 of the Securities Exchange Act of
1934 ('Act') or otherwise subject to the liabilities of that section of the Act
but shall be subject all other provisions of the Act (however, see the Notes).
<PAGE>
<PAGE>
SCHEDULE 13D
CUSIP NO. 216648402 Page 2 of 4 Pages
<TABLE>
<S> <C>
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Cooper Life Sciences, Inc.
94-2563513
- --------------------------------------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not Applicable
- --------------------------------------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- --------------------------------------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------------------------------------------------------------------------------------------------
7 SOLE VOTING POWER
2,192,533 shares of Common Stock
NUMBER OF ------------------------------------------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY -0-
OWNED BY ------------------------------------------------------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 2,192,533 shares of Common Stock
PERSON ------------------------------------------------------------------------------------------------
WITH 10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,192,533 shares of Common Stock
- --------------------------------------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ]
- --------------------------------------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.80%
- --------------------------------------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- --------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
<PAGE>
This Amendment No. 8 amends and supplements Item 5 of the Schedule 13D
filed with the Securities and Exchange Commission on June 22, 1992, as amended
by Amendment No. 1 dated November 12, 1992, Amendment No. 2 dated July 6, 1993,
Amendment No. 3 dated August 24, 1993, Amendment No. 4 dated July 14, 1994,
Amendment No. 5 dated August 15, 1994, Amendment No. 6 dated September 6, 1994,
and Amendment No. 7 dated March 7, 1995 (as amended, the 'Schedule 13D'), by
Cooper Life Sciences, Inc., a Delaware corporation ('CLS'), relating to the
Common Stock, par value $.10 per share (the 'Common Stock') of The Cooper
Companies, Inc., a Delaware corporation (the 'Company'). Except as modified
hereby, there has been no change in the information previously reported in the
Schedule 13D.
Item 5. Interest in Securities of Issuer.
The number of shares of Common Stock which may be deemed to be
beneficially owned by CLS (adjusted for a 1:3 reverse stock split on
September 22, 1995) has decreased by more than 1% of the number of
shares of the class which are deemed to be outstanding. Said decrease is
the result of open market sales of an aggregate of 130,000 shares of
Common Stock, as more fully set forth on Schedule I hereto.
Page 3 of 4 Pages
<PAGE>
<PAGE>
SIGNATURE
After reasonable inquiry, and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
COOPER LIFE SCIENCES, INC.
By: /s/ Steven Rosenberg
------------------------
Name: Steven Rosenberg
Title: Vice President
September 4, 1996
Date
Page 4 of 4 Pages
<PAGE>
<PAGE>
SCHEDULE I
TO AMENDMENT NO. 8 TO SCHEDULE 13D
<TABLE>
<CAPTION>
NO. OF PRICE
NATURE OF SHARES PER
TRANSACTION DATE SOLD SHARE*
- -------------------------------------------------
<S> <C> <C> <C>
Sale 5/30/96 2,400 $12.125
Sale 5/30/96 10,000 $12.00
Sale 5/31/96 57,600 $12.493
Sale 6/3/96 10,000 $13.00
Sale 6/3/96 10,000 $13.125
Sale 8/27/96 10,000 $13.25
Sale 8/27/86 10,000 $13.375
Sale 8/27/96 10,000 $13.50
Sale 8/27/96 10,000 $13.625
TOTAL 130,000
</TABLE>
- ------------
* Before payment of commissions.
